Page 725 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 33 Hematopoietic Tumors 703

TABLE 33.4 Summary of First Remission Outcomes of Combination or Single-Agent Doxorubicin Lymphoma
Chemotherapy Protocols a
VetBooks.ir PRIVATE Protocol No. of Dogs Remission Rate (%) Median Remission % 1-Year Survival References
Duration (Months)
COP 77 75 6.0 19 248
A 37 59 4.4 NR 250
A b 121 85 4.3 NR 246
A 42 74 4.9 NR 239
A + piroxicam 33 79 4.3 NR 239
VMC-L 59 90 4.4 25 236
VMC-L 147 77 4.7 25 237
VCA-L 112 73 7.9 50 116
L-COPA 41 76 11.0 c 48 251
L-COPA(II) 68 75 9.0 c 27 (13 at 2 yr) 240
COPLA/LVP 75 92 (80 ) 5.8 17 415
c
VELCAP-SC 94 70 5.6 44 238
VLCAP-Long 98 69 12.5 c NR 247
L-VCAMP (UW- 55 84 8.4 50 (24 at 2 yr) 235
Madison CHOP)
L-VCAMP 96 79 (CR) 9 NR 234
(continuous 86 90 6.8 c 35 c 243
maintenance
CHOP)
L-VCAMP (+/– 130 94.6 7.3 d NR 245
intensification
CHOP)

L-VCAP (25-week 51 94 9.1 NR 232
CHOP)
L-VCAP-Mx 65 94 10 NR 231
L-VCAP 71 88 9.7 c 32 (13 at 2 yr) 241
L-VCAP (12-week 77 89 8.1 c 28 c 244
CHOP)
VCAP (15-week 31 100 (84 CR) 4.7 d NR 227
CHOP) 134 98 (78 CR) 5.9 d NR 228
L-VCAP/CCNU/ 66 94 10.6 c 46 (35 at 2 yr) 241
MOPrP
COArP 71 92 3 NR 233
L-VCADP 39 100 11 d NR 242
L-VCEP 97 100 (96 CR) 7.2 NR 229

RA 54 98 (68 CR) 6.5 d NR 230
a Minimum of 30 cases required for inclusion. Few of these protocols include sufficient numbers for adequate statistical power and fewer compare treatment protocols in a randomized prospective fashion.
In addition, staging, inclusion, and response criteria vary considerably between protocols presented. Therefore evaluations of efficacy between the various protocols are subject to bias, making direct
comparisons difficult and indeed precarious.
b With COP rescue.
c Only durations of cases achieving CR reported.
d Time to progression.
e Questionable (only one-third reportedly finished).
A, Adriamycin (doxorubicin); Ar, cytosine arabinoside; C, cyclophosphamide; CR, complete response; D, dactinomycin; E, epirubicin; L, l-asparaginase; M, methotrexate; Mx, mitoxantrone; NR, not reported;
O, Oncovin (vincristine); P, prednisone; Pr, procarbazine; R, rabacfosadine; V, vincristine.